Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Major Manufacturers Covered in This Report
• 1.3 Market Segment by Type
  • 1.3.1 Global Interleukin 1 (IL1) Market Size Growth Rate by Type (2019-2025)
  • 1.3.2 APX-002
  • 1.3.3 Canakinumab
  • 1.3.4 Diacerein CR
  • 1.3.5 IR-1000
  • 1.3.6 Others
• 1.4 Market Segment by Application
  • 1.4.1 Global Interleukin 1 (IL1) Market Share by Application (2019-2025)
  • 1.4.2 Esophageal Cancer
  • 1.4.3 Fallopian Tube Cancer
  • 1.4.4 Bladder Cancer
  • 1.4.5 Bechcer Disease
  • 1.4.6 Others
• 1.5 Study Objectives
• 1.6 Years Considered

2 Global Growth Trends

• 2.1 Global Interleukin 1 (IL1) Market Size
  • 2.1.1 Global Interleukin 1 (IL1) Revenue 2014-2025
  • 2.1.2 Global Interleukin 1 (IL1) Sales 2014-2025
• 2.2 Interleukin 1 (IL1) Growth Rate by Regions
  • 2.2.1 Global Interleukin 1 (IL1) Sales by Regions 2014-2019
  • 2.2.2 Global Interleukin 1 (IL1) Revenue by Regions 2014-2019
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers

3 Market Share by Manufacturers

• 3.1 Interleukin 1 (IL1) Sales by Manufacturers
  • 3.1.1 Interleukin 1 (IL1) Sales by Manufacturers 2014-2019
  • 3.1.2 Interleukin 1 (IL1) Sales Market Share by Manufacturers 2014-2019
• 3.2 Revenue by Manufacturers
  • 3.2.1 Interleukin 1 (IL1) Revenue by Manufacturers (2014-2019)
  • 3.2.2 Interleukin 1 (IL1) Revenue Share by Manufacturers (2014-2019)
  • 3.2.3 Global Interleukin 1 (IL1) Market Concentration Ratio (CR5 and HHI)
• 3.3 Interleukin 1 (IL1) Price by Manufacturers
• 3.4 Key Manufacturers Interleukin 1 (IL1) Plants/Factories Distribution and Area Served
• 3.5 Date of Key Manufacturers Enter into Interleukin 1 (IL1) Market
• 3.6 Key Manufacturers Interleukin 1 (IL1) Product Offered
• 3.7 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

• 4.1 Sales and Revenue for Each Type
  • 4.1.1 APX-002 Sales and Revenue (2014-2019)
  • 4.1.2 Canakinumab Sales and Revenue (2014-2019)
  • 4.1.3 Diacerein CR Sales and Revenue (2014-2019)
  • 4.1.4 IR-1000 Sales and Revenue (2014-2019)
  • 4.1.5 Others Sales and Revenue (2014-2019)
• 4.2 Global Interleukin 1 (IL1) Sales Market Share by Type
• 4.3 Global Interleukin 1 (IL1) Revenue Market Share by Type
• 4.4 Interleukin 1 (IL1) Price by Type

5 Market Size by Application

• 5.1 Overview
• 5.2 Global Interleukin 1 (IL1) Sales by Application

6 United States

• 6.1 United States Interleukin 1 (IL1) Breakdown Data by Company
• 6.2 United States Interleukin 1 (IL1) Breakdown Data by Type
• 6.3 United States Interleukin 1 (IL1) Breakdown Data by Application

7 European Union

• 7.1 European Union Interleukin 1 (IL1) Breakdown Data by Company
• 7.2 European Union Interleukin 1 (IL1) Breakdown Data by Type
• 7.3 European Union Interleukin 1 (IL1) Breakdown Data by Application

8 China

• 8.1 China Interleukin 1 (IL1) Breakdown Data by Company
• 8.2 China Interleukin 1 (IL1) Breakdown Data by Type
• 8.3 China Interleukin 1 (IL1) Breakdown Data by Application

9 Rest of World

• 9.1 Rest of World Interleukin 1 (IL1) Breakdown Data by Company
• 9.2 Rest of World Interleukin 1 (IL1) Breakdown Data by Type
• 9.3 Rest of World Interleukin 1 (IL1) Breakdown Data by Application
• 9.4 Rest of World Interleukin 1 (IL1) Breakdown Data by Countries
  • 9.4.1 Rest of World Interleukin 1 (IL1) Sales by Countries
  • 9.4.2 Rest of World Interleukin 1 (IL1) Revenue by Countries
  • 9.4.3 Japan
  • 9.4.4 Korea
  • 9.4.5 India
  • 9.4.6 Southeast Asia

10 Company Profiles

• 10.1 Optimum Therapeutics LLC
  • 10.1.1 Optimum Therapeutics LLC Company Details
  • 10.1.2 Company Description and Business Overview
  • 10.1.3 Sales, Revenue and Market Share of Interleukin 1 (IL1)
  • 10.1.4 Interleukin 1 (IL1) Product Introduction
  • 10.1.5 Optimum Therapeutics LLC Recent Development
• 10.2 Orphit SAS
  • 10.2.1 Orphit SAS Company Details
  • 10.2.2 Company Description and Business Overview
  • 10.2.3 Sales, Revenue and Market Share of Interleukin 1 (IL1)
  • 10.2.4 Interleukin 1 (IL1) Product Introduction
  • 10.2.5 Orphit SAS Recent Development
• 10.3 Peptinov SAS
  • 10.3.1 Peptinov SAS Company Details
  • 10.3.2 Company Description and Business Overview
  • 10.3.3 Sales, Revenue and Market Share of Interleukin 1 (IL1)
  • 10.3.4 Interleukin 1 (IL1) Product Introduction
  • 10.3.5 Peptinov SAS Recent Development
• 10.4 AbbVie Inc
  • 10.4.1 AbbVie Inc Company Details
  • 10.4.2 Company Description and Business Overview
  • 10.4.3 Sales, Revenue and Market Share of Interleukin 1 (IL1)
  • 10.4.4 Interleukin 1 (IL1) Product Introduction
  • 10.4.5 AbbVie Inc Recent Development
• 10.5 Swedish Orphan Biovitrum AB
  • 10.5.1 Swedish Orphan Biovitrum AB Company Details
  • 10.5.2 Company Description and Business Overview
  • 10.5.3 Sales, Revenue and Market Share of Interleukin 1 (IL1)
  • 10.5.4 Interleukin 1 (IL1) Product Introduction
  • 10.5.5 Swedish Orphan Biovitrum AB Recent Development
• 10.6 TWi Biotechnology Inc
  • 10.6.1 TWi Biotechnology Inc Company Details
  • 10.6.2 Company Description and Business Overview
  • 10.6.3 Sales, Revenue and Market Share of Interleukin 1 (IL1)
  • 10.6.4 Interleukin 1 (IL1) Product Introduction
  • 10.6.5 TWi Biotechnology Inc Recent Development
• 10.7 XBiotech Inc
  • 10.7.1 XBiotech Inc Company Details
  • 10.7.2 Company Description and Business Overview
  • 10.7.3 Sales, Revenue and Market Share of Interleukin 1 (IL1)
  • 10.7.4 Interleukin 1 (IL1) Product Introduction
  • 10.7.5 XBiotech Inc Recent Development
• 10.8 Cell Medica Ltd
  • 10.8.1 Cell Medica Ltd Company Details
  • 10.8.2 Company Description and Business Overview
  • 10.8.3 Sales, Revenue and Market Share of Interleukin 1 (IL1)
  • 10.8.4 Interleukin 1 (IL1) Product Introduction
  • 10.8.5 Cell Medica Ltd Recent Development
• 10.9 Exicure Inc
  • 10.9.1 Exicure Inc Company Details
  • 10.9.2 Company Description and Business Overview
  • 10.9.3 Sales, Revenue and Market Share of Interleukin 1 (IL1)
  • 10.9.4 Interleukin 1 (IL1) Product Introduction
  • 10.9.5 Exicure Inc Recent Development
• 10.10 Immune Response BioPharma Inc
  • 10.10.1 Immune Response BioPharma Inc Company Details
  • 10.10.2 Company Description and Business Overview
  • 10.10.3 Sales, Revenue and Market Share of Interleukin 1 (IL1)
  • 10.10.4 Interleukin 1 (IL1) Product Introduction
  • 10.10.5 Immune Response BioPharma Inc Recent Development
• 10.11 Novartis AG
• 10.12 Omnitura Therapeutics Inc
• 10.13 Opsona Therapeutics Ltd
• 10.14 Anacor Pharmaceuticals Inc
• 10.15 Apexigen Inc
• 10.16 R Pharm
• 10.17 Regeneron Pharmaceuticals Inc

11 Value Chain and Sales Channels Analysis

• 11.1 Value Chain Analysis
• 11.2 Sales Channels Analysis
  • 11.2.1 Interleukin 1 (IL1) Sales Channels
  • 11.2.2 Interleukin 1 (IL1) Distributors
• 11.3 Interleukin 1 (IL1) Customers

12 Market Forecast

• 12.1 Global Interleukin 1 (IL1) Sales and Revenue Forecast 2019-2025
• 12.2 Global Interleukin 1 (IL1) Sales Forecast by Type
• 12.3 Global Interleukin 1 (IL1) Sales Forecast by Application
• 12.4 Interleukin 1 (IL1) Forecast by Regions
  • 12.4.1 Global Interleukin 1 (IL1) Sales Forecast by Regions 2019-2025
  • 12.4.2 Global Interleukin 1 (IL1) Revenue Forecast by Regions 2019-2025
• 12.5 United States Market Forecast
• 12.6 European Union Market Forecast
• 12.7 China Market Forecast
• 12.8 Rest of World
  • 12.8.1 Japan
  • 12.8.2 Korea
  • 12.8.3 India

13 Research Findings and Conclusion

14 Appendix

• 14.1 Research Methodology
  • 14.1.1 Methodology/Research Approach
    • 14.1.1.1 Research Programs/Design
    • 14.1.1.2 Market Size Estimation
    • 14.1.1.3 Market Breakdown and Data Triangulation
  • 14.1.2 Data Source
    • 14.1.2.1 Secondary Sources
    • 14.1.2.2 Primary Sources
• 14.2 Author Details

In 2019, the market size of Interleukin 1 (IL1) is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Interleukin 1 (IL1).

This report studies the global market size of Interleukin 1 (IL1), especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Interleukin 1 (IL1) sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

In global market, the following companies are covered:
Optimum Therapeutics LLC
Orphit SAS
Peptinov SAS
AbbVie Inc
Swedish Orphan Biovitrum AB
TWi Biotechnology Inc
XBiotech Inc
Cell Medica Ltd
Exicure Inc
Immune Response BioPharma Inc
Novartis AG
Omnitura Therapeutics Inc
Opsona Therapeutics Ltd
Anacor Pharmaceuticals Inc
Apexigen Inc
R Pharm
Regeneron Pharmaceuticals Inc

Market Segment by Product Type
APX-002
Canakinumab
Diacerein CR
IR-1000
Others

Market Segment by Application
Esophageal Cancer
Fallopian Tube Cancer
Bladder Cancer
Bechcer Disease
Others

Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)

The study objectives are:
To analyze and research the Interleukin 1 (IL1) status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Interleukin 1 (IL1) manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

In this study, the years considered to estimate the market size of Interleukin 1 (IL1) are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025